Effectiveness of Low-Dose Aspirin in Preventing Pre-Eclampsia in High-Risk Pregnant Women: A Randomized Controlled Trial in Tertiary Care Hospitals

Maham  Aslam; Hira Iqba

doi:10.54112/bcsrj.v6i3.1641

Authors

Maham Aslam Deparment of Obs & Gynae, Jamila Fareedi Medical Center, Lahore, Pakistan
Hira Iqba Deparment of Obs & Gynae, Fatima Jinnah Hospital Multan, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v6i3.1641

Keywords:

Pre-eclampsia, low-dose aspirin, high-risk pregnancy, maternal health, Pakistan, randomized controlled trial

Abstract

Pre-eclampsia is a leading cause of maternal and perinatal morbidity and mortality in Pakistan. Low-dose aspirin (LDA) has been identified as a promising preventive strategy for high-risk pregnancies when initiated early. This study aimed to evaluate the effectiveness of daily low-dose aspirin in preventing pre-eclampsia and improving maternal and neonatal outcomes in a tertiary care setting. Methods: This randomized controlled trial was conducted at a tertiary care hospital in Pakistan over six months (August 2024 to January 2025). A total of 86 high-risk pregnant women were randomly assigned to either the aspirin group (75 mg/day from 12–16 to 36 weeks of gestation) or the control group receiving routine antenatal care. Data on maternal blood pressure, proteinuria, and clinical outcomes were collected and compared. Perinatal outcomes were also recorded, including birth weight, gestational age at delivery, and NICU admission. Statistical analysis was performed using SPSS v26, with p < 0.05 considered significant. Results: Pre-eclampsia occurred in 13.9% of women in the aspirin group versus 34.9% in the control group (p = 0.02). Severe pre-eclampsia was significantly lower in the aspirin group (4.7% vs. 20.9%, p = 0.03). Rates of preterm delivery, low birth weight, and NICU admission were significantly reduced among aspirin users. Additionally, the intervention group better controlled systolic and diastolic blood pressures and proteinuria levels. Conclusion: Low-dose aspirin is effective in reducing the incidence and severity of pre-eclampsia in high-risk pregnancies. It is a safe, inexpensive, and accessible intervention that can significantly improve maternal and neonatal outcomes in the Pakistani population when introduced early in antenatal care.

Downloads

Download data is not yet available.

References

Pasha O, McClure EM, Saleem S, et al. A prospective cause of death classification system for maternal deaths in low and middle-income countries: Results from the Global Network Maternal Newborn Health Registry. BJOG. 2020;127(6):738–47.

Jabeen M, Soomro N, Kazi RA, et al. Hypertensive disorders during pregnancy and maternal mortality in Pakistan: a national review. J Pak Med Assoc. 2021;71(3):763–7.

Imran M, Abbas A, Malik MA. Frequency and outcomes of pre-eclampsia in a tertiary care hospital: A clinical audit. Pak J Med Sci. 2022;38(1):200–5.

Baloch SN, Zubair M, Sher Z, et al. Risk factors and maternal outcomes associated with pre-eclampsia in Pakistani women. J Coll Physicians Surg Pak. 2020;30(5):475–9.

Khaskheli MN, Baloch S, Sheeba A. Complications and outcomes of pre-eclampsia in a tertiary care hospital. Cureus. 2021;13(2):e13223.

Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613–22.

American College of Obstetricians and Gynecologists (ACOG). Low-dose aspirin use during pregnancy. ACOG Committee Opinion No. 743. Obstet Gynecol. 2018;132(1):e44–52.

World Health Organization. WHO recommendations: Antenatal care for a positive pregnancy experience. Geneva: World Health Organization; 2016.

Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preeclampsia and intrauterine growth restriction. Clin Lab Med. 2016;36(2):319–29.

Meher S, Duley L, Hunter KE, et al. Antiplatelet therapy before or during pregnancy, or after delivery, for preventing pre‐eclampsia and its complications. Cochrane Database Syst Rev. 2021;2021(2): CD004659.

Khanum A, Rehman F, Sattar A, et al. Low-dose aspirin for pre-eclampsia prevention in Pakistani population: a randomized controlled trial. Pak J Obstet Gynaecol. 2022;12(2):75–80.

Niaz K, Abbasi F, Mahmood A. Effectiveness of aspirin in reducing adverse maternal outcomes in high-risk pregnancies: a randomized trial in Pakistan. J Pak Med Assoc. 2023;73(1):22–6.

Shaheen A, Wahab F, Ali S. Maternal and fetal outcomes of low-dose aspirin in high-risk pregnancies: Evidence from a tertiary hospital in Lahore. J Obstet Gynaecol Res. 2020;46(9):1794–9.

Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613–22.

Rolnik DL, Wright D, Syngelaki A, et al. Impact of aspirin on neonatal outcomes in pregnancies at high risk of preterm preeclampsia: A secondary analysis of the ASPRE trial. BJOG. 2018;125(8):985–91.

Meher S, Duley L, Hunter KE, et al. Antiplatelet therapy before or during pregnancy, or after delivery, for preventing pre‐eclampsia and its complications. Cochrane Database Syst Rev. 2021;2(2): CD004659.

Khanum A, Rehman F, Sattar A, et al. Low-dose aspirin for pre-eclampsia prevention in Pakistani population: a randomized controlled trial. Pak J Obstet Gynaecol. 2022;12(2):75–80.

Uzan J, Carbonnel M, Piconne O, et al. Pre-eclampsia: pathophysiology, diagnosis, and management. Vasc Health Risk Manag. 2011;7:467–74.

Niaz K, Abbasi F, Mahmood A. Effectiveness of aspirin in reducing adverse maternal outcomes in high-risk pregnancies: a randomized trial in Pakistan. J Pak Med Assoc. 2023;73(1):22–6.

Pasha O, McClure EM, Saleem S, et al. A prospective cause of death classification system for maternal deaths in low- and middle-income countries: results from the Global Network Maternal Newborn Health Registry. BJOG. 2020;127(6):738–47.